newsfilter
← Latest News
GlobeNewswire·

Telix to Host R&D Day in New York City on September 22, 2026

  • Telix Pharmaceuticals Limited will host an R&D Day on September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
  • The in-person session targets institutional investors & analysts to review the company's therapeutic & precision medicine pipeline, scientific developments, & strategic updates.
  • Telix leadership presenting includes CEO Dr. Christian Behrenbruch, CMO Dr. David N. Cade, CEO Therapeutics Richard Valeix, CEO Precision Medicine Kevin Richardson, & VP Discovery Sciences Dr. Michael Wheatcroft.
  • Advance registration is required for the R&D Day, with venue & agenda details provided upon confirmation via contacts Annie Kasparian or Charlene Jaw.
  • Telix will also host a Capital Markets Day in Melbourne on November 4, 2026, to discuss strategy, growth outlook, financial targets, & business priorities.
  • Both events are restricted to qualified institutional investors & analysts.
  • Telix operates as a commercial-stage radiopharmaceutical company with a prostate cancer imaging franchise anchored by Illuccix® & Gozellix®.
  • The company's late-stage pipeline includes TLX591-Tx for prostate cancer, TLX101-Tx for recurrent glioblastoma, & TLX250-Tx for kidney cancer.
  • Telix is headquartered in Melbourne, Australia, with global operations across North America, Europe, Latin America, & Asia-Pacific.